You are right, a new 6 mill share offering with the market cap being 300 mill not 30. What we need it some news dribble from the Adipotide trial and we will skyrocket. Buy out at the 3 bill level is plausible given replication of the ape weightloss in humans, no more.
This is exactly the problem I warned against some time back. Their cash burn is way too high. They are just hoping for the money to flow back into the rnai space OR for some deal to happen or some clinical success that they can use to dump more shares into the market. Risky bet. If nothing happens this company is either toast just like MRNA or they need to downsize again.
1) shares were trading greater the $3.40 and the best offering they could get was 2.76. That ought to tell you something. 2) This mgmt has a long history of not knowing what they're doing. Why would anybody think that's changed?
Sure 6,5 mill is a lot with a market cap of 30 mill. But taken into account the pipe, muiltiple companies acquired it should trade at 300 miil. Then a 6 mill shelf offering is nothing. And we can hope for partnering and sales to commence. All in all there arent any other pharmas that give more bang for the buck than Arrow. Thats why I bought into it at this time.